AREV Nutrition Sciences Inc. Announces Adrian Wade, URSA Technologies as Project Management & the Formation of an Advisory Committee

Tickers: XCNQ:ARV
Tags: Mining

Vancouver, British Columbia / TheNewswire / December 7, 2017 – AREV Nutrition Sciences Inc. ("AREV" or the "Company") (CNSX – ARV), is pleased to announce that Adrian Wade through URSA Technologies has joined the team as project manager of AREV effective immediately. Further, AREV has formed an advisory committee made up of Adrian Wade, Ph.D, Christina Juneau, Ph.D, and Dr. Shabtai Bittman.

Adrian P. Wade Ph.D., C.Chem., MRSC, MCIC, MCSC – Dr. Wade is an analytical chemist and computer scientist who is currently the Chief Science Officer of Alternative Extracts Inc. He has published over 50 scientific papers, including work in automated chemical analysis, flow injection analysis, automated extraction methods and chromatography. He is Co-owner and Manager of Ursa Technologies Ltd. (founded 1994), which provides chemistry consulting services and undertakes research and development in process analytical chemistry and methods development. He taught analytical chemistry at University of British Columbia (1987-94) and was a Visiting Research Associate at Michigan State University (1985-87). He obtained his Ph.D. from University of Wales in 1985, and his B.Sc. from University of Southampton in 1981. He serves as a Director and Officer for Alternative Extracts Inc. where he is responsible for science and methods development. Since 2005 he has served as a Director of Goknet Mining Company Ltd., where he provides scientific and technical expertise relating to their projects in Ghana. He recently joined the Board of UC Resources Ltd as an independent Director. He is a resident of British Columbia.

Dr Christina Juneau is the Scientific Director at TransBIOTech and she holds a B.Sc in Biochemistry and a Ph.D. in Food Science, both from Universite Laval. Dr Juneau has more than 25 years of experience in the pharmaceutical and biotechnology industry, more specifically in the conception and development of therapeutic products, in the manufacturing processes, in the regulatory aspects related to oral and topical drugs and natural health products development, as well as in the intellectual properties and market introduction aspects of various compounds. She has an extensive experience in the design and management of applied R&D projects and she is the co-author on more than 20 patents and peer reviewed scientific articles.

Dr. Shabtai BittmanDr. Bittman is a principal research scientist with Agriculture and Agri-Food Canada in Agassiz, BC, and previously in SK and NS, specializing in crop production. He studied and taught Plant Ecology at McGill University and Crop Physiology (water stress) at the University of Saskatchewan. His research has been focused on minimizing environmental impacts of food production with advanced cropping and nutrient management practices. Recent efforts include the reduction of emissions of nitrogenous gases and particulates to the atmosphere and the improvement of water quality through strategic manure use. Dr. Bittman developed the Canadian Agri-Environmental Health Indicator for Atmospheric Ammonia and co-chairs the UNECE Expert Panel on Mitigating Agricultural Nitrogen. He has won national and international awards for his research accomplishments. He founded and operates the website

For a more complete list of Dr. Shabtai Bittman’s significant achievements, it can be found at

"We are honored to welcome this group of experienced individuals as advisory committee members," said Stephane Maher, CEO. "The selected AREV members are all exceptional professionals and leaders in their respective field. I anticipate each member will be a great asset to the company and represent AREV commitment to be a leader in the natural health and cannabis industries."

The Company, effective immediately, has issued Mr. Wade 25,000 stock options as a signing bonus for agreeing to be the project manager at AREV and the Company has agreed to issue Mr. Wade and additional 25,000 stock options at the successful implementation of a project management system. Further the Company will be issuing 25,000 stock options to Mr. Wade agreeing to join the Company’s Advisory Committee. The Company has also agreed to provide Christina Juneau, Ph.D 50,000 stock options for joining the Advisory Committee.

For further information, contact Stephane Maher, CEO at

On behalf of the Board,

Stephane Maher
Chief Executive Officer & Director

About AREV Nutrition Sciences Inc.
AREV Nutrition Sciences Inc. ("AREV"), produces and delivers functional ingredients from its world-class extraction system. AREV is revolutionizing the current delivery method of coconut oil, whey protein and nutrients through emulsification. These premium ingredients and products are targeted for the natural health, medical, functional food, nutraceutical, sport nutrition and bioceutical markets. AREV is also working with Pharmacy and Dispensary operators with an innovative emulsified base formula to disperse Cannabis oil extracts from specific selected genetic Cannabis strains that address 5 areas of health including Anxiety, Pain management, Insomnia, Central Nervous System Disorders & Sexuality.



Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company’s Management’s Discussion and Analysis under the Company’s profile on

Copyright (c) 2017 TheNewswire – All rights reserved. – RSS (all)